Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · 20/20 Biolabs, Inc. (AIDX)

20/20 BioLabs Q2 revenue rises 36.5% to $0.7 million; net loss widens to $1.5 million

Mixed Impact 3 of 5 earnings Written later

20/20 BioLabs reported second-quarter 2026 revenue of $0.7 million, up 36.5% from the prior year, and gross margin of 41.7%, up from 30.5%. Net loss widened to $1.5 million from $0.8 million, which the filing attributes partly to one-time Nasdaq listing costs and about $0.7 million in non-cash charges, and the company ended the quarter with $4.5 million in cash and no convertible note debt.

Key points

  • Q2 2026 revenue was $0.7 million, up 36.5% from $0.5 million; OneTest revenue rose 47.1% to $0.7 million.
  • Gross margin was 41.7% in Q2 2026, compared with 30.5% a year earlier.
  • Operating expenses rose to $1.5 million from $1.0 million, mainly from Nasdaq direct listing costs and product development.
  • Net loss was $1.5 million, versus $0.8 million, and cash and cash equivalents were $4.5 million as of June 30, 2026.

The filing

Company20/20 Biolabs, Inc. (AIDX)
Form8-K, current report
Filed with the SECAug 17, 2026, 4:05 PM ET
Accession number0001213900-26-090746

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.